Intravaginal oestrogen and progestin administration: advantages and disadvantages

Ettore Cicinelli
Best practice & research. Clinical obstetrics & gynaecology · 2007 · vol. 22(2) , pp. 391–405 · doi:10.1016/j.bpobgyn.2007.08.010 · PMID:17981510 · W2116072919
review OA: closed CC0 ⤵ 7 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06, 2026-06-10 ⓘ

This paper reviews the advantages and disadvantages of administering estrogen and progestin intravaginally.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

MeSH descriptors

Estrogens Progestins Administration, Intravaginal Atrophy Atrophy Breast Neoplasms Breast Neoplasms Danazol Danazol Endometrial Hyperplasia Endometrial Hyperplasia Estrogen Antagonists Estrogen Antagonists Estrogens Estrogens Estrogens Female Humans Progestins Progestins

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (56)

Cited by (7)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:14:48.452140+00:00
License: CC0 · commercial use OK